Journal of thrombosis and haemostasis : JTH · 2025
Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial.
СтатьяКлиническое исследование III фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kavakli Kaan, Cuker Adam, Frenzel Laurent, Wang Jiaan-Der, Bagot Catherine N, Sahin Fahri, Tran Huyen, Alzahrani Hazzaa, Matino Davide, Rupon Jeremy, McKay John, Wilcox Lisa J, Biondo Francesca, Agathon Delphine, Thakkar Sheena, Sun Pengling, Plonski Frank, von Mackensen Sylvia
Аннотация
BACKGROUND: BENEGENE-2 is an ongoing phase 3 trial of fidanacogene elaparvovec, an adeno-associated virus gene therapy vector delivering a high-activity factor (F)IX variant, FIX-R338L (FIX-Padua).
OBJECTIVES: To assess patient-reported outcome measures in BENEGENE-2.
METHODS: Eligible males (N = 45) with hemophilia B received a single fidanacogene elaparvovec infusion after ≥6 months of FIX prophylaxis. Participants completed assessments pre- and post-gene therapy, including the Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL), Hemophilia Activities List (HAL), Patient Global Impression of Change-Hemophilia, Hemophilia Life Impacts Questionnaire, and European Quality of Life 5-Dimensions 5-levels.
RESULTS: Post-gene therapy, more participants (64.4% vs 28.9%) were free from bleeds compared with pre-gene therapy. Overall, 64.4% of participants did not require exogenous FIX infusions post-gene therapy. Changes from pre- to week 52 post-gene therapy suggested improved health-related quality of life in the key secondary endpoints of the Haem-A-QoL Physical Health domain (mean [SD] score change, -7.7 [15.8]; P = .005) and the HAL Complex Lower Extremity Activities score (mean [SD] score change, 7.6 [19.6]; P = .024). Additionally, there was a mean (SD) improvement of -11.2 (9.1), P < .001, in the Haem-A-QoL total score, and 6.7 (10.9), P < .001, in the HAL total score. In the exploratory endpoints, changes in the European Quality of Life 5-Dimensions 5-levels index score (mean [SD] score change, 0.05 [0.10]; P = .003) and visual analog scale (mean [SD] score change, 5.8 [15.6]; P = .030) suggested improved health status. Overall, 56.1% of participants reported that their overall impression of life with hemophilia (Patient Global Impression of Change-Hemophilia) had "greatly improved." Improvements were observed in Hemophilia Life Impacts Questionnaire domains related to living with and treating hemophilia.
CONCLUSION: Fidanacogene elaparvovec improved health-related quality of life and health and functional status in adults with hemophilia B.
OBJECTIVES: To assess patient-reported outcome measures in BENEGENE-2.
METHODS: Eligible males (N = 45) with hemophilia B received a single fidanacogene elaparvovec infusion after ≥6 months of FIX prophylaxis. Participants completed assessments pre- and post-gene therapy, including the Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL), Hemophilia Activities List (HAL), Patient Global Impression of Change-Hemophilia, Hemophilia Life Impacts Questionnaire, and European Quality of Life 5-Dimensions 5-levels.
RESULTS: Post-gene therapy, more participants (64.4% vs 28.9%) were free from bleeds compared with pre-gene therapy. Overall, 64.4% of participants did not require exogenous FIX infusions post-gene therapy. Changes from pre- to week 52 post-gene therapy suggested improved health-related quality of life in the key secondary endpoints of the Haem-A-QoL Physical Health domain (mean [SD] score change, -7.7 [15.8]; P = .005) and the HAL Complex Lower Extremity Activities score (mean [SD] score change, 7.6 [19.6]; P = .024). Additionally, there was a mean (SD) improvement of -11.2 (9.1), P < .001, in the Haem-A-QoL total score, and 6.7 (10.9), P < .001, in the HAL total score. In the exploratory endpoints, changes in the European Quality of Life 5-Dimensions 5-levels index score (mean [SD] score change, 0.05 [0.10]; P = .003) and visual analog scale (mean [SD] score change, 5.8 [15.6]; P = .030) suggested improved health status. Overall, 56.1% of participants reported that their overall impression of life with hemophilia (Patient Global Impression of Change-Hemophilia) had "greatly improved." Improvements were observed in Hemophilia Life Impacts Questionnaire domains related to living with and treating hemophilia.
CONCLUSION: Fidanacogene elaparvovec improved health-related quality of life and health and functional status in adults with hemophilia B.